The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow,Elias Campo,Stefano Pileri,Nancy L. Harris,Harald Stein,Reiner Siebert,Ranjana H. Advani,Michele Ghielmini,Gilles Salles,Andrew D. Zelenetz,Elaine S. Jaffe +10 more
Reads0
Chats0
TLDR
The revision clarifies the diagnosis and management of lesions at the very early stages of lymphomagenesis, refines the diagnostic criteria for some entities, details the expanding genetic/molecular landscape of numerous lymphoid neoplasms and their clinical correlates, and refers to investigations leading to more targeted therapeutic strategies.About:
This article is published in Blood.The article was published on 2016-05-19 and is currently open access. It has received 5321 citations till now.read more
Citations
More filters
Journal ArticleDOI
Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: A report of three cases
Andrea Visentin,Silvia Imbergamo,Federica Frezzato,Marco Pizzi,Roberta Bertorelle,Edoardo Scomazzon,Tamara Berno,Marcello Riva,Elisa Piva,Monica Facco,Francesco Piazza,Gianpietro Semenzato,Livio Trentin +12 more
TL;DR: Bendamustine plus rituximab proved to be an effective and feasible first-line treatment strategy for elderly patients with TP53 un-mutated HCLv and is still in complete remission after a median follow-up of 19 months.
Journal ArticleDOI
Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma.
Jayadev Manikkam Umakanthan,Javeed Iqbal,Connie Lee Batlevi,Alyssa Bouska,Lynette M. Smith,Valerie Shostrom,Heather Nutsch,Basem M. William,R. Gregory Bociek,Mathew Lunning,Philip J. Bierman,Anas Younes,James O. Armitage,Julie M. Vose +13 more
TL;DR: Dasatinib showed modest activity in evaluable patients with an objective response rate of 29% and clinical benefit rate of 71% and the side effect profile was consistent with prior studies, with pleural effusion being the most common non‐haematological toxicity.
Journal ArticleDOI
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells
TL;DR: This work builds on a compendium of resistant mutations to small molecule inhibitors reported in the literature and provides a comprehensive review ofresistant mutations in cancers, and discusses mechanistic parallels of resistance.
Journal ArticleDOI
Regulation of EBV LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma and its impact on patients' survival
Ya Chi Huang,Sue Jane Lin,Sue Jane Lin,Kai-Min Lin,Ya Ching Chou,Chung-Wu Lin,Shan Chi Yu,Chi Long Chen,Tang Long Shen,Chi Kuan Chen,Chi Kuan Chen,Jean Lu,Mei-Ru Chen,Ching-Hwa Tsai +13 more
TL;DR: A novel mechanism by which erythropoietin-producing hepatocellular receptor A4 (EphA4), which belongs to the largest RTK Eph family, was downregulated in primary B cells post-EBV infection at the transcriptional and translational levels is provided.
Journal ArticleDOI
The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.
Yang Xia,Xinlian Zhang +1 more
TL;DR: It has been proved that cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab show limited effects for DHL or DE-DLBCL, and the ritUXimab plus dose-adjusted etoposide, prednis one, v incristine and doxorbicin seem to be efficacious for D HL.
References
More filters
Book
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
TL;DR: Thank you very much for reading who classification of tumours of haematopoietic and lymphoid tissues, and maybe you have knowledge that, people have look hundreds of times for their chosen readings like this, but end up in malicious downloads.
Journal ArticleDOI
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.
TL;DR: The criteria and significance of early or precursor lesions and the identification of certain lymphoid neoplasms largely associated with particular age groups, such as children and the elderly are addressed, and the issue of borderline categories having overlapping features with large B-cell lymphomas is reviewed.
Journal ArticleDOI
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Xose S. Puente,Magda Pinyol,Víctor Quesada,Laura Conde,Gonzalo R. Ordóñez,Neus Villamor,Geòrgia Escaramís,Pedro Jares,Sílvia Beà,Marcos González-Díaz,Laia Bassaganyas,Tycho Baumann,Manel Juan,Mónica López-Guerra,Dolors Colomer,Jose M. C. Tubio,Cristina López,Alba Navarro,Cristian Tornador,Marta Aymerich,María Rozman,Jesús M. Hernández,Diana A. Puente,José M.P. Freije,Gloria Velasco,Ana Gutiérrez-Fernández,Dolors Costa,Anna Carrió,Sara Guijarro,Anna Enjuanes,Lluis Hernández,Jordi Yagüe,Pilar Nicolás,Carlos M. Romeo-Casabona,Heinz Himmelbauer,Ester Castillo,Juliane C. Dohm,Silvia de Sanjosé,Miguel A. Piris,Enrique de Alava,Jesús F. San Miguel,Romina Royo,Josep Lluís Gelpí,David Torrents,Modesto Orozco,David G. Pisano,Alfonso Valencia,Roderic Guigó,Mònica Bayés,Simon Heath,Marta Gut,Peter Klatt,John Marshall,Keiran Raine,Lucy Stebbings,P. Andrew Futreal,Michael R. Stratton,Peter J. Campbell,Ivo Gut,Armando López-Guillermo,Xavier Estivill,Emili Montserrat,Carlos López-Otín,Elias Campo +63 more
TL;DR: The patterns of somatic mutation, supported by functional and clinical analyses, strongly indicate that the recurrent NOTCH1, MYD88 and XPO1 mutations are oncogenic changes that contribute to the clinical evolution of the disease.
Journal ArticleDOI
MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
Steven P. Treon,Lian Xu,Guang Yang,Yangsheng Zhou,Xia Liu,Yang Cao,Patricia Sheehy,Robert Manning,Christopher J. Patterson,Christina K. Tripsas,Luca Arcaini,Geraldine S. Pinkus,Scott J. Rodig,Aliyah R. Sohani,Nancy L. Harris,Jason M. Laramie,Donald A Skifter,Stephen E Lincoln,Zachary R. Hunter +18 more
TL;DR: MYD88 L265P is a commonly recurring mutation in patients with Waldenström's macroglobulinemia that can be useful in differentiating WaldenStröm’s macrogalobulinesia and non-IgM LPL from B-cell disorders that have some of the same features.
Related Papers (5)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
Christine P. Hans,Dennis D. Weisenburger,Timothy C. Greiner,Randy D. Gascoyne,Jan Delabie,German Ott,H. Konrad Muller-Hermelink,Elias Campo,Rita M. Braziel,Elaine S. Jaffe,Zenggang Pan,Pedro Farinha,Lynette M. Smith,Brunangelo Falini,Alison H. Banham,Andreas Rosenwald,Louis M. Staudt,Joseph M. Connors,James O. Armitage,Wing C. Chan +19 more
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Ash A. Alizadeh,Michael B. Eisen,R. Eric Davis,Izidore S. Lossos,Andreas Rosenwald,Jennifer C. Boldrick,Hajeer Sabet,Truc Tran,Xin Yu,John Powell,Liming Yang,Gerald E. Marti,Troy Moore,James I. Hudson,Li-Sheng Lu,David B. Lewis,Robert Tibshirani,Gavin Sherlock,Wing C. Chan,Timothy C. Greiner,Dennis D. Weisenburger,James O. Armitage,Roger A. Warnke,Ronald Levy,Wyndham H. Wilson,M. R. Grever,John C. Byrd,David Botstein,Patrick O. Brown,Louis M. Staudt +29 more